NCT04550845 Understanding of Genetics by Men at Risk for Prostate Cancer
| NCT ID | NCT04550845 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2027-09-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2023-05-01 with a primary completion date of 2027-09-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understanding of prognostic genetic technology in African American and rural White men at risk for localized prostate cancer.
Eligibility Criteria
Inclusion Criteria: * African-American or White men * Living in a rural or urban areas * Age 40 to 95 years old * Able and willing to provide informed consent * English-speaking * Willing to participate in the study. This study will use the United States Department of Agriculture Office of Rural Development's definition of rural, which is as a city or town that has a population less than 50,000 inhabitants to define rural. This study will use the United States Census Bureau's definition of urban, which is a city or town that has a population greater than 50,000 inhabitants to define urban. Exclusion Criteria: Women will be excluded from participating in this study. However, women will be recruited to serve on an advisory panel to review the video-based educational tool for the comprehension of genomic terminology for prognostic genetic testing in patients with localized prostate cancer.
Contact & Investigator
Ewan K Cobran, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT04550845 clinical trial?
This trial is open to male participants only, aged 40 Years or older, up to 95 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04550845 currently recruiting?
Yes, NCT04550845 is actively recruiting participants. Contact the research team at cobran.ewan@mayo.edu for enrollment information.
Where is the NCT04550845 trial being conducted?
This trial is being conducted at Phoenix, United States, Jacksonville, United States, Rochester, United States.
Who is sponsoring the NCT04550845 clinical trial?
NCT04550845 is sponsored by Mayo Clinic. The principal investigator is Ewan K Cobran, PhD at Mayo Clinic. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.